Filament BioSolutions Inc. is a medical foods and functional foods company dedicated to improving the health of patients with diseases that cause nutritional deficiencies. We apply the principles of scientific rigor and evidence-based nutrition to establish clinical efficacy for our products.
We are biopharmaceutical executives, physicians, and nutrition scientists committed to the highest scientific standards of clinical and commercial development. Our collaborators are leaders in biotechnology, the food industry, and academia.
Our goal is to establish a world-class pipeline of commercial and development stage products by earning credibility with physicians and payors on a product-by-product basis with a long term horizon. We believe that creating value goes hand-in-hand with building trust with patients and stakeholders.
Thomas Cirrito Ph.D. is also a co-founder of Immunovent, a development stage biotechnology company developing a next-generation, non-invasive allergy diagnostic, and Biotagenics, a platform company that is developing therapeutics and diagnostics based on a proprietary database of clinical samples from patients with inflammatory bowel disease. Dr. Cirrito previously served as Vice President of Research and Development and Director of Business Development at Stemline Therapeutics (NASDAQ: STML) since March 2012. Dr. Cirrito joined Stemline in 2005 as the second full-time employee, and was responsible for business development, preclinical, intellectual property, manufacturing, analytical, and operations. Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously, he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group. Dr. Cirrito received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, Missouri). He currently serves on the Scientific and Business Advisory Board of the Alzheimer's Drug Discovery Foundation. He serves as an investor and mentor to early stage biotechnology and health care companies.
Bradley Theien MS MBA joined Filament from Pfizer, where he was part of the Strategy, Portfolio and Commercial Operations group and led a team that supported clinical and investment decisions for Pfizer’s Worldwide R&D organization. Prior to Pfizer, Mr. Theien was a managing consultant for bioStrategies Group, a life science consulting firm focused on developing commercial strategies for new and existing healthcare products and technologies. Mr. Theien also was a biopharmaceutical equity analyst at Prudential Securities where he covered several small-cap biotechnology companies. He has authored two papers on homing of T cells from the periphery into the CNS and previously researched neural mechanisms of taste-guided behavior. Mr. Theien received a MS in Biotechnology and an MBA from Northwestern University.
Kate Rochlin Ph.D. is a Co-Founder and Chief Scientific Officer of Immunovent, a development stage biotechnology company creating a next-generation, non-invasive allergy diagnostic. Her responsibilities include directing the research & development program, business development and management of the preclinical program. Dr. Rochlin completed her Ph.D. at Cornell University in New York City, where her work focused on muscular dystrophy and the role of RNA regulation in muscle-tendon attachment. Prior to this Dr. Rochlin worked at the University of Pennsylvania School of Medicine studying signaling in metastatic cancer. Dr. Rochlin earned her BA from the University of Pennsylvania.
Jason Rosenberg is a Co-Founder of Jibon Health Technologies, a Columbia University biotech start-up focused on medical technologies for developing countries that has won several international awards and accolades. Mr. Rosenberg also worked at FINCA, one of the largest microfinance institutions, supporting the creation of an impact fund for healthcare and solar technologies in their Social Enterprise and Financial Innovation department. He received a BS from University of Wisconsin – Madison.
Zeil Rosenberg MD MPH is VP of Medical Affairs at Admera Health, an advanced molecular diagnostics company, where he works on precision medicine and non-invasive cancer testing. His executive experience includes leadership positions in a wide range of business and clinical settings including CEO of a publicly traded medical nutrition company, Worldwide Medical Director for Immunization at Becton Dickinson (BD), and National Medical Director at the Children’s Health Fund. Dr. Rosenberg earned his MD from UCSF, MPH from Columbia and his BA from Stanford. He is a Specialty Fellow of the American Academy of Pediatrics and Fellow of the American College of Preventive Medicine and the New York Academy of Medicine. He served as AAS Science, Engineering and Diplomacy Fellow and is currently an adjunct faculty member at Columbia’s Mailman School of Public Health.
David S. Seres MD ScM PNS is Director of Medical Nutrition and Associate Professor of Medicine, Columbia University College of Physicians and Surgeons and Institute of Human Nutrition, where he directs the Nutrition Support Service and the medical and dental school nutrition curriculum. He has been a nutrition support practitioner for 23 years. He is former Chair of Physician Certification for the National Board of Nutrition Support Certification, and of the Medical Practice Section of the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). He was recently named to the Medical Advisory Board of Consumer Reports. He has coauthored safety guidelines, and multiple chapters and invited reviews, and appears frequently on the media advocating against dangerous consumer foods and nutritional practices.
Elliot Goodman MD is a Pioneer in new techniques in endoluminal gastric surgery. He joined the medical staff of Beth Israel Medical Center in January, 2004. Previously, he was chief of bariatric surgery at Montefiore Medical Center. He is on the surgical faculty of the Albert Einstein College of Medicine. Before coming to New York, he was on the faculty of the New Jersey Medical School and was the Co-Director of the University Institute for the Surgery of Morbid Obesity. Dr. Goodman is an active member of the American Society of Bariatric Surgeons. His clinical interests include general and bariatric surgery. He has considerable research experience studying how immunosuppressive medications improve the success of organ transplants. Dr. Goodman received his undergraduate and medical school education at Cambridge University, and trained in general surgery at Maimonides Medical Center in Brooklyn. He is also a USA/Israel venture partner to GCV Life - a healthcare investment bank based in Mumbai, India.
Filament is developing FB-2710 for cancer patients undergoing chemotherapy and radiation who are at risk of developing oral mucositis and peripheral neuropathy, among other side effects of treatment.
In healthy individuals, glutamine is not an essential amino acid; however, in patients undergoing treatment for cancer, glutamine can become "conditionally" deficient, putting these patients at risk of developing severe toxicities, including oral mucositis and peripheralneuropathy. The oncologist will often lower or delay a dose of chemotherapy or radiation therapy due to the severity of these toxicities.
FB-2710 is a proprietary formulation, using an optimal analog of glutamine that provides convenient administration for the patient with improved bioavailability. FB-2710 is designed to ameliorate the side effects of chemotherapy, to improve the quality of life for patients, and decrease the severity of the side effects of their treatment.
Filament BioSolutions and Ajinomoto have entered into a broad collaboration to develop a portfolio of high quality, clinically-validated medical and functional food products. Under the collaboration, Ajinomoto supplies ingredients and amino acids used in a variety of Filament therapeutic products. Ajinomoto also supports Filament’s product and clinical activities through collaboration with its basic and clinical scientists, food technologists, and technical capabilities. As a component of this partnership; Ajinomoto has provided financing to Filament to accelerate the growth of the company and the development of its product portfolio.
Filament Biosolutions and Biotagenics have entered into a strategic R&D partnership to explore the interface of clinical nutrition and the microbiome. This collaboration will develop an in-depth understanding of the impact of nutrition on the microbiome and role of microbiome in regulating the body’s nutritional status. This research is expected to lead to the development of advanced diagnostics, therapeutics, and medical foods that will compliment both companies existing product platforms.
Filament is actively seeking innovative products and opportunities for partnering or in-licensing of medical nutrition candidates that complement our existing product portfolio and infrastructure.
brad.theien(at)filamentbiosolutions.com to discuss partnership or licensing opportunities.
Filament BioSolutions Inc. is located in New York, NY. We can be reached via info (at) filamentbiosolutions.com.